Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
5.75    -0.10 (-1.71%)
Bid:
5.70
Ask:
5.80
Spread: 0.10 (1.754%)
Market Cap: £61.50m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

EXECUTIVE CHANGES: Hansard Global hires new CEO; Argentex co-CEO back

Mon, 10th May 2021 15:01

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

----------

Hansard Global PLC - Isle of Man-based specialist long-term savings provider - Hires Graham Sheward as chief executive officer, starting immediately. Sheward replaces Gordon Marr, who Hansard announced in March is retiring. Sheward most recently was the Isle of Man-based managing director of the local office of Sancus Group. He has worked for a number of offshore financial services businesses, including those of Natwest Group PLC, Barclays PLC and Close Brothers Group PLC.

----------

Argentex Group PLC - London-based foreign exchange services - Co-CEO Carl Jani returns to work on Monday following a leave of absence for health reasons that began in January. Co-CEO Harry Adams had assumed the role of sole CEO during Jani's absence.

----------

Conygar Investment Co PLC - London-based property investment and development - Promotes Financial Controller David Baldwin to finance director, effective from Monday. Baldwin has been financial controller for five years and company secretary for the past year.

----------

Inspired Energy PLC - Kirkham, Lancashire-based consultant for energy procurement, utility cost optimisation and legislative compliance - Promotes Richard Logan from independent non-executive director to non-executive chair, starting from end of annual general meeting on June 30. Logan replaces Mike Fletcher, who steps down after nine years on the board. Also hires Sangita Shah as independent non-executive director, starting July 1. Shah is chair of AIM listings Bilby PLC and RA International Group PLC.

----------

Ergomed PLC - Guildford, England-based services to pharmaceutical industry - Hires Mark Enyedy as non-executive director, starting June 10. Enyedy is CEO of ImmunoGen Inc, a Nasdaq-listed biotechnology firm. Prior to ImmunoGen, Enyedy worked at Shire PLC as head of Corporate Development.

----------

Shield Therapeutics PLC - Newcastle, England-based pharmaceutical firm focused on iron deficiency - Hires Fabiana Lacerca-Allen and Anders Lundstrom as independent non-executive directors, starting immediately. Lacerca-Allen is chief compliance officer for Aimmune Therapeutics Inc in San Francisco. Aimmune is part of Nestle SA. Lundstrom is chief commercial officer at High Point, North Carolina-based Banner Life Sciences.

----------

Templeton Emerging Markets Investment Trust PLC - Hires Magdalene Miller as non-executive director, starting Monday. Miller is a former investment director with Aberdeen Standard Investments' global emerging market team.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related News

LONDON MARKET CLOSE: Miners lift FTSE 100 while oil price heads lower
1 day ago

LONDON MARKET CLOSE: Miners lift FTSE 100 while oil price heads lower

(Alliance News) - The FTSE 100 made steady progress on Tuesday, with events in the Middle East continuing to largely dictate the market mood.

IN BRIEF: Social Housing REIT targets increased payout for this year
2 days ago

IN BRIEF: Social Housing REIT targets increased payout for this year

Social Housing REIT PLC - London-based real estate investment company - Declares 1.45 pence per share ordinary dividend for the first quarter. Says it...

IN BRIEF: NatWest divisional CEO Emma Crystal sells GBP294,820 shares
5 days ago

IN BRIEF: NatWest divisional CEO Emma Crystal sells GBP294,820 shares

NatWest Group PLC - Edinburgh-based lender - Emma Crystal, chief executive Private Banking & Wealth Management sells 50,000 shares at 589.64 pence eac...

Shield Thera News

EARNINGS AND TRADING: ProService Building Services lowers outlook
1 May 2026

EARNINGS AND TRADING: ProService Building Services lowers outlook

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...

LONDON MARKET MIDDAY: FTSE falls as US-Iran talks stall
1 May 2026

LONDON MARKET MIDDAY: FTSE falls as US-Iran talks stall

(Alliance News) - Stock prices in London were lower at midday on Friday, as hopes of diplomatic progress in the Middle East, and a batch of domestic d...

Shield Therapeutics reports positive Q1 earnings
1 May 2026

Shield Therapeutics reports positive Q1 earnings

(Sharecast News) - Shield Therapeutics reported first-quarter net revenue of $18m and positive EBIT on Friday, helped by a China milestone payment and...

WINNERS & LOSERS: Shield Therapeutics down on Medicaid concerns
1 May 2026

WINNERS & LOSERS: Shield Therapeutics down on Medicaid concerns

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday.

TRADING UPDATES: Zenith Energy picks up two solar projects in Italy
27 Apr 2026

TRADING UPDATES: Zenith Energy picks up two solar projects in Italy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Shield Therapeutics expects "strong" Accrufer growth as revenue rises
9 Apr 2026

Shield Therapeutics expects "strong" Accrufer growth as revenue rises

(Alliance News) - Shield Therapeutics PLC on Thursday highlighted a record performance from Accrufer, which it said helped drive a strong rise in annu...

Shield's Accrufer MA application accepted in China
3 Mar 2026

Shield's Accrufer MA application accepted in China

(Sharecast News) - Shield Therapeutics said the Chinese National Medical Products Administration has accepted a marketing authorisation application fo...

IN BRIEF: Shield Therapeutics gets three more years of US exclusivity
9 Feb 2026

IN BRIEF: Shield Therapeutics gets three more years of US exclusivity

Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Says the US Food & Drug Administration grants an addition...